ClinicalTrials.gov record
Completed Phase 2 Interventional

A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders

ClinicalTrials.gov ID: NCT02125318

Public ClinicalTrials.gov record NCT02125318. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 2:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Open Label Efficacy and Safety Study of Anagrelide Controlled Release (CR) in Subjects With Thrombocytosis Secondary to Essential Thrombocythemia and Other Myeloproliferative Neoplasms (MPN)

Study identification

NCT ID
NCT02125318
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Galena Biopharma, Inc.
Industry
Enrollment
18 participants

Conditions and interventions

Interventions

  • Anagrelide CR Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2014
Primary completion
Apr 30, 2016
Completion
Apr 30, 2016
Last update posted
Feb 26, 2017

2014 – 2016

United States locations

U.S. sites
11
U.S. states
6
U.S. cities
11
Facility City State ZIP Site status
East Valley Hematology and Oncology Medical Group Burbank California 91505
California Cancer Associates for Research & Excellence (cCARE) Encinitas California 92024
California Cancer Associates for Research & Excellence (cCARE) Escondido California 92025
California Cancer Associates For Research and Excellence Fresno California 93720
Innovative Medical Research of South Florida, Inc. Aventura Florida 33180
Cancer Center of Kansas Wichita Kansas 67214
Wake Forest Baptist Health Winston-Salem North Carolina 27157
Gettysburg Cancer Center Hillsdale Pennsylvania 17325
The University of Texas MD Anderson Cancer Center Houston Texas 77030
Cancer Care Centers of South Texas New Braunfels Texas 78130
Cancer Care Centers of South Texas San Antonio Texas 78229

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02125318, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 26, 2017 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02125318 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →